Clinical Trials Logo

Psychomotor Agitation clinical trials

View clinical trials related to Psychomotor Agitation.

Filter by:

NCT ID: NCT01415323 Completed - Mental Disorders Clinical Trials

Agitation in the Acute Psychiatric Department

Start date: September 2011
Phase:
Study type: Observational

Agitation is associated with a number of acute psychiatric conditions, and frequent in acute psychiatric admissions. It is associated with violence towards others, and strongly associated with in-patient suicides. The main aims of the study are to assess different clinical presentations of agitation at admittance, and to assess the consequences of these different clinical presentations during the first three days of the stay.

NCT ID: NCT01386944 Completed - Clinical trials for Restless Legs Syndrome

Effect on RLS Symptom Severity After Switching to Neupro® in Patients Who Previously Experienced Augmentation

AURORA
Start date: July 2011
Phase:
Study type: Observational

The objective is to assess the effect of Neupro® on the severity of Restless Leg Syndrome (RLS) symptoms and augmentation in patients with augmentation associated with previous oral dopaminergic therapy. In addition, the change in treatment regimen used when switching to Neupro® will be evaluated.

NCT ID: NCT01382901 Completed - Clinical trials for Restless Legs Syndrome (RLS)

Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)

Start date: March 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study was to evaluate the safety of 2 dosage regimens of Intravenous (IV) iron Ferric Carboxymaltose (FCM) in comparison to placebo in patients with Restless Legs Syndrome (RLS)

NCT ID: NCT01362959 Completed - Delirium Clinical Trials

Nicotine Replacement Therapy in the Intensive Care Unit

NicGoWell
Start date: June 2012
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether transdermal nicotine replacement therapy is safe and effective for treating nicotine withdrawal symptoms in the critically ill smoking patient.

NCT ID: NCT01332318 Completed - Clinical trials for Restless Legs Syndrome

Simulated Driving Study in Restless Legs Syndrome

XP083
Start date: April 2007
Phase: Phase 2
Study type: Interventional

This study was a multi center, randomized, double blind, active and placebo controlled, parallel group study to assess simulated driving performance in XP13512 treated subjects with Restless Legs Syndrome (RLS). Eligible subjects were randomized to receive a once daily dose of placebo (2 groups), XP13512 1200 mg, or XP13512 1800 mg for 16 days. On Day 16, one of the placebo groups also received one 50 mg dose of diphenhydramine (DPH) to assess the effects of an agent known to have sedative properties, while the other 3 groups received a DPH placebo.

NCT ID: NCT01332305 Completed - Clinical trials for Restless Legs Syndrome

Dose-Response and Pharmacokinetics of Gabapentin Enacarbil (GEn [XP13512 / GSK1838262]) in Restless Legs Syndrome

XP081
Start date: January 2007
Phase: Phase 2
Study type: Interventional

The objective of the study was to generate the data necessary to determine the gabapentin exposure produced by 4 dose levels of GEn (600 mg, 1200 mg, 1800 mg, and 2400 mg) or placebo, and the corresponding relief of symptoms in subjects with Restless Legs Syndrome (RLS).

NCT ID: NCT01327339 Completed - Clinical trials for Restless Legs Syndrome

REQUIP RLS Post Marketing Surveillance

REQUIP RLS PMS
Start date: April 2006
Phase: N/A
Study type: Observational

post-marketing surveillance to monitor safety and efficacy of ropinirole during using of treatment for RLS

NCT ID: NCT01245777 Completed - Clinical trials for Iron Deficiency Anemia

Restless Legs Syndrome With Iron Deficiency or Anaemia in the 3rd Trimester of Pregnancy

Start date: October 2009
Phase: Phase 4
Study type: Interventional

In pregnancy Restless Legs Syndrome(RLS) is more common than in the general population. During pregnancy iron tablets are the only available safe medication but their efficacy is rather poor. It is the aim of this study to examine the efficacy, practicability and safety of the drug Ferinject® containing the active agent Ferric carboxymaltose for the therapy of Restless Legs Syndrome(RLS) during pregnancy in the case of iron deficiency or anaemia. 20 women with RLS and iron deficiency and/ or anaemia in the third trimester of pregnancy will receive intravenous Ferric carboxymaltose in one or two single doses. Repeated blood tests, pre-and post-therapy actigraphy as well as repeated answering of questionnaires concerning Restless Legs Syndrome(RLS)-symptoms and sleep quality will show the effect of iv-Iron supplementation on Restless Legs Syndrome(RLS)-symptoms during pregnancy. - Trial with medicinal product

NCT ID: NCT01193816 Completed - Restlessness Clinical Trials

Loxapine in the Management of Restlessness During Mechanical Ventilation Weaning

Sevralox
Start date: May 2011
Phase: Phase 4
Study type: Interventional

This study aims to assess the efficacy of a drug (loxapine, a neuroleptic) in calming patients down in a situation of restlessness during mechanical ventilation weaning. This drug is used for several years to quieten restless patients. Its purpose is to restore spontaneous breathing sooner and therefore to reduce the risks of intubation and mechanical ventilation.

NCT ID: NCT01174459 Completed - Clinical trials for Restless Legs Syndrome

Survey on Long-Term Use of BI-Sifrol® Tablets in Patients With Restless Legs Syndrome

Start date: August 2010
Phase: N/A
Study type: Observational

The survey is conducted to investigate the safety and efficacy of long-term use of BI-Sifrol Tablets in Restless Legs Syndrome (RLS) patients with or without renal dysfunction in routine medical practice.